News

The financing was led by Hillhouse Capital Management and Quan Capital, and included Bay City Capital, Surveyor Capital (a Citadel company), Ping An Ventures, Taiho Ventures LLC, ArrowMark

The FDA designation for the Tecentriq chemo combination is for TNBC patients whose condition is unresectable locally advanced or metastatic and whose disease expresses the PD-L1 protein, as

The analysis, which is part of the 3b Expedition-8 study, assessed the safety and efficacy of Mavyret in treatment-naïve chronic hepatitis C virus (HCV) patients with compensated cirrhosis

Synagis is indicated for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in highly prone infants and is the only approved

The FDA and the Company have agreed to meet in-person on January 31, 2019 to discuss this matter. Remoxy is the proposed trade name for a new type

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. CRISPR

Aimmune Therapeutics is engaged in the development of advanced treatments for life-threatening food allergies. The latest investment brings Nestlé’s total investment in the drug developer for food allergies

The priority review for Lynparza (olaparib) is for the maintenance treatment of such patients who had shown complete or partial response after first-line standard platinum-based chemotherapy. The FDA

OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment. Harpoon’s existing investors MPM Capital, Oncology